Forecasted sales of top hemophilia products worldwide 2026
In 2026, the hemophilia drug Hemlibra is forecasted to generate 5.6 billion U.S. dollars worldwide in sales revenue, while NovoSeven is forecasted to generate 796 million U.S. dollars in sales revenue. This statistic illustrates the forecasted sales of top hemophilia products worldwide in 2026.